ClinicalTrials.gg
RecruitingNCT06362473LIPIGENUpdated Nov 10, 2026

Lipid Transport Disorder Italian Genetic Record (LIPIGEN)

An observational study in Familial Hypercholesterolemia and Genetic Disorder, sponsored by Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi). Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Observational

How we know

From the registry’s dates

  • Started Aug 2015; still recruiting 11 years 3 months later.
Updated Nov 10, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
15,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Hyperlipoproteinemia Type II with a site in Italy — 4 open to participants now, 4 under way, 2 of them phase 3. Hyperlipoproteinemia Type II · Italy.

Started
2015
with 1 other
Observational
4 of 19
2 open now
Registered
18th of 19
by date
Lead sponsor
2 of 19
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)

Among the 19 studies in Hyperlipoproteinemia Type II with a site in Italy, this one is one of 2 that started in 2015, is one of 4 observational ones, and was the 18th registered.

Hyperlipoproteinemia Type II

251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

4 of the 19 studies in Hyperlipoproteinemia Type II with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hyperlipoproteinemia Type II with a site in Italy, or all of them as a file.
02

Study summary

LIPIGEN is an observational study involving Italian physicians and researchers in the field of diseases related to blood lipid levels. This study aims to improve the diagnosis and treatment of people with familial dyslipidaemias, including very common conditions such as familial hypercholesterolaemia (FH) and less common ones such as familial chylomicronidaemic syndrome (FCS).

What does the study do?

It collects information on Italian patients with Familial Hypercholesterolaemia (FH), following them in their normal clinical examination without adding extra procedures.

It uses the data collected to further our understanding of diseases such as familial hypercholesterolaemia, examining how it is diagnosed clinically and by genetic testing, and evaluating the effectiveness of different treatments.

It seeks to identify the genetic mutations that cause familial hypercholesterolaemia and other dyslipidaemias, helping to choose the most effective treatments.

It evaluates the impact of long-term treatments and patient adherence to medication, as well as monitoring the incidence of cardiovascular events and other important outcomes.

Who can participate?

The study is aimed at people of all ages, from children to adults, with familial hypercholesterolaemia or other genetic dyslipidaemia.

More than 50 centres throughout Italy are involved, making the study accessible to many.

What does participation entail?

Participants will continue with their normal clinical practice.

Data such as family history, personal clinical findings and genetic information will be collected, without additional procedures.

For some, further evaluations, such as ultrasounds, may be required to better study their condition.

The LIPIGEN study not only helps to better understand diseases related to high cholesterol but also aims to improve patients\' lives through more precise diagnosis and personalised treatments.

03

Conditions studied

  • Familial Hypercholesterolemia
  • Genetic Disorder

Keywords

  • LIPIGEN
  • Familial Hypercholesterelomia
  • Genetic Dyslipidemia
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with molecular or clinical diagnosis of genetic dyslipidemia of any age or sex.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Molecular or clinical diagnosis of genetic dyslipidemia
  • signed

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
15,000 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes

Interventions

  • DrugLipid-lowering treatments
06

What researchers measure

Primary outcomes

  1. Lipid profile of patients with genetic dyslipidemia

    Lipid profile of patients with molecular or clinical diagnosis of genetic dyslipidemia: * LDL cholesterol (mg/dL) * Total cholesterol (mg/dL) * HDL cholesterol (mg/dL) * Triglycerides (mg/dL) * Lipoprotein (a) (mg/dL), if available

    Time frame: At baseline and through study completion up to 20 years

  2. Genetic profile of patients with genetic dyslipidemia

    Genetic profile of patients with molecular or clinical diagnosis of genetic dyslipidemia: * Prevalance (%) of patients with pathogenic/likely pathogenic variants on candidate genes * Prevalance (%) of patients with variants of uncertain significance (VUS) on candidate genes * Distribution (%) of more common variants

    Time frame: At baseline evaluation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Averna M, Cefalu AB, Casula M, Noto D, Arca M, Bertolini S, Calandra S, Catapano AL, Tarugi P; LIPIGEN Group. Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atheroscler Suppl. 2017 Oct;29:11-16. doi: 10.1016/j.atherosclerosissup.2017.07.001. PubMed 28965615 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2015 (actual). Primary completion is estimated for Dec 2036, 256 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Sep 2026 → Dec 2036 and completion Sep 2026 → Dec 2036.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 12, 2024
StartActual
Aug 4, 2015
Primary completionEst.
Dec 31, 2036was Sep 2026
CompletionEst.
Dec 31, 2036was Sep 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • IRCCS Multimedica · Sesto San Giovanni, Italy
Show 1 removed
  • IRCCS Multimedica · Sesto san Giovanni, Italy
Nov 10, 2026
Primary completion
Sep 30, 2026→Dec 31, 2036
Nov 10, 2026
Study completion
Sep 30, 2026→Dec 31, 2036
Nov 10, 2026
Enrollment
10000→15000
Nov 10, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameLipid profile of patients with genetic dyslipidemiaAt baseline evaluation → At baseline and through study completion up to 20 years
Nov 10, 2026
Contact
Study contact's phone or email changed: •••8428→•••8428. See the current contact
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    1 site added, 1 site removed
    Show site
    • IRCCS Multimedica · Sesto San Giovanni, Italy
    Show 1 removed
    • IRCCS Multimedica · Sesto san Giovanni, Italy
    Primary completion Sep 30, 2026→Dec 31, 2036
    Study completion Sep 30, 2026→Dec 31, 2036
    Enrollment 10000→15000
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameLipid profile of patients with genetic dyslipidemiaAt baseline evaluation → At baseline and through study completion up to 20 years
    Contact Study contact's phone or email changed: •••8428→•••8428. See the current contact
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06362473
Lead sponsor
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
Responsible party
Sponsor
First posted
Apr 12, 2024
Start date
Aug 4, 2015
Primary completion
Dec 31, 2036 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
Nov 10, 2026

Study contacts

Manuela Casula, PhD
Contact
manuela.casula@unimi.it
+390250318428
Alberico L Catapano, PhD
study chair · Fondazione S.I.S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion